Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model.

Anfuso B, Tiribelli C, Adorini L, Rosso N.

Sci Rep. 2020 Feb 3;10(1):1699. doi: 10.1038/s41598-020-58562-x.

2.

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.

Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J.

BMC Gastroenterol. 2019 Dec 28;19(1):228. doi: 10.1186/s12876-019-1149-z.

3.

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.

Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M.

J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.

4.

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.

McIlvride S, Nikolova V, Fan HM, McDonald JAK, Wahlström A, Bellafante E, Jansen E, Adorini L, Shapiro D, Jones P, Marchesi JR, Marschall HU, Williamson C.

Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E399-E410. doi: 10.1152/ajpendo.00407.2018. Epub 2019 Jun 25.

5.

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.

Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH.

Sci Rep. 2019 Jun 21;9(1):9046. doi: 10.1038/s41598-019-45178-z.

6.

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.

Di Matteo S, Nevi L, Costantini D, Overi D, Carpino G, Safarikia S, Giulitti F, Napoletano C, Manzi E, De Rose AM, Melandro F, Bragazzi M, Berloco PB, Giuliante F, Grazi G, Giorgi A, Cardinale V, Adorini L, Gaudio E, Alvaro D.

PLoS One. 2019 Jan 24;14(1):e0210077. doi: 10.1371/journal.pone.0210077. eCollection 2019.

7.

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corno C, Adorini L, Vannelli GB, Maggi M, Vignozzi L.

J Endocrinol Invest. 2019 Aug;42(8):951-965. doi: 10.1007/s40618-019-1009-2. Epub 2019 Jan 23.

PMID:
30674010
8.

FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice.

Iracheta-Vellve A, Calenda CD, Petrasek J, Ambade A, Kodys K, Adorini L, Szabo G.

Hepatol Commun. 2018 Oct 15;2(11):1379-1391. doi: 10.1002/hep4.1256. eCollection 2018 Nov.

9.

FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.

Friedman ES, Li Y, Shen TD, Jiang J, Chau L, Adorini L, Babakhani F, Edwards J, Shapiro D, Zhao C, Carr RM, Bittinger K, Li H, Wu GD.

Gastroenterology. 2018 Dec;155(6):1741-1752.e5. doi: 10.1053/j.gastro.2018.08.022. Epub 2018 Aug 23.

10.

TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice.

Eblimit Z, Thevananther S, Karpen SJ, Taegtmeyer H, Moore DD, Adorini L, Penny DJ, Desai MS.

Cardiovasc Ther. 2018 Oct;36(5):e12462. doi: 10.1111/1755-5922.12462. Epub 2018 Aug 22.

11.

INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.

Comeglio P, Cellai I, Mello T, Filippi S, Maneschi E, Corcetto F, Corno C, Sarchielli E, Morelli A, Rapizzi E, Bani D, Guasti D, Vannelli GB, Galli A, Adorini L, Maggi M, Vignozzi L.

J Endocrinol. 2018 Aug;238(2):107-127. doi: 10.1530/JOE-17-0557.

PMID:
29945982
12.

Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model.

Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corno C, Pini A, Adorini L, Vannelli GB, Maggi M, Vignozzi L.

J Endocrinol Invest. 2019 Mar;42(3):283-294. doi: 10.1007/s40618-018-0913-1. Epub 2018 Jun 19.

PMID:
29923060
13.

Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in db/db Mice.

Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, Prasad R, Bhatwadekar A, White FA, Townsend SD, Chan L, Ryan CN, Morton D, Moldovan EG, Chu FI, Oudit GY, Derendorf H, Adorini L, Wang XX, Evans-Molina C, Mirmira RG, Boulton ME, Yoder MC, Li Q, Levi M, Busik JV, Grant MB.

Diabetes. 2018 Sep;67(9):1867-1879. doi: 10.2337/db18-0158. Epub 2018 Apr 30.

14.

Megatrends in bile acid receptor research.

Adorini L, Schoonjans K, Friedman SL.

Hepatol Commun. 2017 Aug 24;1(8):831-835. doi: 10.1002/hep4.1085. eCollection 2017 Oct. No abstract available.

15.

Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.

Jadhav K, Xu Y, Xu Y, Li Y, Xu J, Zhu Y, Adorini L, Lee YK, Kasumov T, Yin L, Zhang Y.

Mol Metab. 2018 Mar;9:131-140. doi: 10.1016/j.molmet.2018.01.005. Epub 2018 Jan 11.

16.

The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.

Ferrigno A, Di Pasqua LG, Berardo C, Siciliano V, Rizzo V, Adorini L, Richelmi P, Vairetti M.

PLoS One. 2018 Jan 18;13(1):e0191430. doi: 10.1371/journal.pone.0191430. eCollection 2018.

17.

FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.

Wang XX, Wang D, Luo Y, Myakala K, Dobrinskikh E, Rosenberg AZ, Levi J, Kopp JB, Field A, Hill A, Lucia S, Qiu L, Jiang T, Peng Y, Orlicky D, Garcia G, Herman-Edelstein M, D'Agati V, Henriksen K, Adorini L, Pruzanski M, Xie C, Krausz KW, Gonzalez FJ, Ranjit S, Dvornikov A, Gratton E, Levi M.

J Am Soc Nephrol. 2018 Jan;29(1):118-137. doi: 10.1681/ASN.2017020222. Epub 2017 Oct 31.

18.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.

Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Marschall HU, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones D; Obeticholic Acid PBC Monotherapy Study Group.

Hepatology. 2018 May;67(5):1890-1902. doi: 10.1002/hep.29569. Epub 2018 Jan 29.

19.

Beneficial effects of bile acid receptor agonists in pulmonary disease models.

Comeglio P, Morelli A, Adorini L, Maggi M, Vignozzi L.

Expert Opin Investig Drugs. 2017 Nov;26(11):1215-1228. doi: 10.1080/13543784.2017.1385760. Epub 2017 Oct 3. Review.

PMID:
28949776
20.

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Agüero R, Olaizola P, Caro-Maldonado A, Martín-Martín N, Carracedo A, Lozano E, Marin JJ, O'Rourke CJ, Andersen JB, Llop J, Gómez-Vallejo V, Padro D, Martin A, Marzioni M, Adorini L, Trauner M, Bujanda L, Perugorria MJ, Banales JM.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1335-1344. doi: 10.1016/j.bbadis.2017.08.016. Epub 2017 Sep 13.

21.

A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.

Wang XX, Luo Y, Wang D, Adorini L, Pruzanski M, Dobrinskikh E, Levi M.

J Biol Chem. 2017 Jul 21;292(29):12018-12024. doi: 10.1074/jbc.C117.794982. Epub 2017 Jun 8.

22.

Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells.

Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, Keely SJ.

FASEB J. 2017 Sep;31(9):3848-3857. doi: 10.1096/fj.201601365R. Epub 2017 May 9.

PMID:
28487283
23.

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis.

Roda A, Aldini R, Camborata C, Spinozzi S, Franco P, Cont M, D'Errico A, Vasuri F, Degiovanni A, Maroni L, Adorini L.

Clin Transl Sci. 2017 Jul;10(4):292-301. doi: 10.1111/cts.12468. Epub 2017 May 23.

24.

Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.

Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corcetto F, Corno C, Maneschi E, Pini A, Adorini L, Vannelli GB, Maggi M, Vignozzi L.

J Steroid Biochem Mol Biol. 2017 Apr;168:26-37. doi: 10.1016/j.jsbmb.2017.01.010. Epub 2017 Jan 20.

PMID:
28115235
25.

Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.

Vignozzi L, Morelli A, Cellai I, Filippi S, Comeglio P, Sarchielli E, Maneschi E, Vannelli GB, Adorini L, Maggi M.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):277-292. doi: 10.1016/j.jsbmb.2016.07.004. Epub 2016 Jul 15.

PMID:
27425465
26.

Farnesoid X receptor activation increases reverse cholesterol transport by modulating bile acid composition and cholesterol absorption in mice.

Xu Y, Li F, Zalzala M, Xu J, Gonzalez FJ, Adorini L, Lee YK, Yin L, Zhang Y.

Hepatology. 2016 Oct;64(4):1072-85. doi: 10.1002/hep.28712. Epub 2016 Jul 30.

27.

G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes.

Wang XX, Edelstein MH, Gafter U, Qiu L, Luo Y, Dobrinskikh E, Lucia S, Adorini L, D'Agati VD, Levi J, Rosenberg A, Kopp JB, Gius DR, Saleem MA, Levi M.

J Am Soc Nephrol. 2016 May;27(5):1362-78. doi: 10.1681/ASN.2014121271. Epub 2015 Sep 30.

28.

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D.

Gastroenterology. 2015 Apr;148(4):751-61.e8. doi: 10.1053/j.gastro.2014.12.005. Epub 2014 Dec 11.

29.

Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat.

Roda A, Pellicciari R, Gioiello A, Neri F, Camborata C, Passeri D, De Franco F, Spinozzi S, Colliva C, Adorini L, Montagnani M, Aldini R.

J Pharmacol Exp Ther. 2014 Jul;350(1):56-68. doi: 10.1124/jpet.114.214650. Epub 2014 May 1.

PMID:
24784847
30.

Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.

Vignozzi L, Filippi S, Comeglio P, Cellai I, Sarchielli E, Morelli A, Rastrelli G, Maneschi E, Galli A, Vannelli GB, Saad F, Mannucci E, Adorini L, Maggi M.

Mol Cell Endocrinol. 2014 Mar 25;384(1-2):143-54. doi: 10.1016/j.mce.2014.01.014. Epub 2014 Jan 31.

PMID:
24486698
31.

Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits.

Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, Rastrelli G, Maneschi E, Cellai I, Persani L, Adorini L, Vannelli GB, Maggi M.

Mol Cell Endocrinol. 2014 Jan 25;382(1):107-119. doi: 10.1016/j.mce.2013.09.017. Epub 2013 Sep 21.

PMID:
24064031
32.

Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis.

Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, Jadhav K, Adorini L, Zhang Y.

Hepatology. 2014 May;59(5):1761-1771. doi: 10.1002/hep.26714. Epub 2014 Apr 1.

33.

FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS.

Maneschi E, Vignozzi L, Morelli A, Mello T, Filippi S, Cellai I, Comeglio P, Sarchielli E, Calcagno A, Mazzanti B, Vettor R, Vannelli GB, Adorini L, Maggi M.

J Endocrinol. 2013 Jul 6;218(2):215-31. doi: 10.1530/JOE-13-0109. Print 2013.

PMID:
23750014
34.

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D.

Gastroenterology. 2013 Sep;145(3):574-82.e1. doi: 10.1053/j.gastro.2013.05.042. Epub 2013 May 30.

PMID:
23727264
35.

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR.

J Biol Chem. 2013 Apr 26;288(17):11761-70. doi: 10.1074/jbc.M112.446575. Epub 2013 Mar 4.

36.

Testosterone protects the lower urinary tract from metabolic syndrome-induced alterations.

Vignozzi L, Morelli A, Corona G, Sebastianelli A, Serni S, Gacci M, Adorini L, Maggi M.

Horm Mol Biol Clin Investig. 2012 Oct;11(2):329-37. doi: 10.1515/hmbci-2012-0029.

PMID:
25436692
37.

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.

Adorini L, Pruzanski M, Shapiro D.

Drug Discov Today. 2012 Sep;17(17-18):988-97. doi: 10.1016/j.drudis.2012.05.012. Epub 2012 May 29. Review.

PMID:
22652341
38.

Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.

Marinozzi M, Carotti A, Sansone E, Macchiarulo A, Rosatelli E, Sardella R, Natalini B, Rizzo G, Adorini L, Passeri D, De Franco F, Pruzanski M, Pellicciari R.

Bioorg Med Chem. 2012 Jun 1;20(11):3429-45. doi: 10.1016/j.bmc.2012.04.021. Epub 2012 Apr 20.

PMID:
22564381
39.

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.

Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, Filippi S, Logiodice F, Carini M, Nesi G, Gacci M, Piccinni MP, Adorini L, Maggi M.

J Endocrinol. 2012 Jul;214(1):31-43. doi: 10.1530/JOE-12-0142. Epub 2012 May 4. Erratum in: J Endocrinol. 2012 Aug;214(2):239.

PMID:
22562653
40.

Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.

Pellicciari R, Gioiello A, Sabbatini P, Venturoni F, Nuti R, Colliva C, Rizzo G, Adorini L, Pruzanski M, Roda A, Macchiarulo A.

ACS Med Chem Lett. 2012 Feb 6;3(4):273-7. doi: 10.1021/ml200256d. eCollection 2012 Apr 12.

41.

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.

Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L, Yehiely-Cohen R, Maneschi E, Gacci M, Carini M, Adorini L, Vannelli GB, Maggi M.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):80-92. doi: 10.1016/j.jsbmb.2012.02.007. Epub 2012 Mar 8.

PMID:
22406511
42.

TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading.

Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, Auwerx J, Schoonjans K.

Cell Metab. 2011 Dec 7;14(6):747-57. doi: 10.1016/j.cmet.2011.11.006.

43.

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.

Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, Maneschi E, Serni S, Gacci M, Carini M, Piccinni MP, Saad F, Adorini L, Vannelli GB, Maggi M.

J Endocrinol. 2012 Jan;212(1):71-84. doi: 10.1530/JOE-11-0289. Epub 2011 Oct 18.

PMID:
22010203
44.

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Baghdasaryan A, Claudel T, Gumhold J, Silbert D, Adorini L, Roda A, Vecchiotti S, Gonzalez FJ, Schoonjans K, Strazzabosco M, Fickert P, Trauner M.

Hepatology. 2011 Oct;54(4):1303-12. doi: 10.1002/hep.24537.

45.

Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis.

McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L, Uskokovic MR, El-Nazir B, Murphy P, Greally P, Greene CM, McElvaney NG.

J Cyst Fibros. 2011 Dec;10(6):428-34. doi: 10.1016/j.jcf.2011.06.013. Epub 2011 Jul 23.

46.

Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility.

Lotti F, Corona G, Colpi GM, Filimberti E, Degli Innocenti S, Mancini M, Baldi E, Noci I, Forti G, Adorini L, Maggi M.

J Endocrinol Invest. 2011 Nov;34(10):e336-42. doi: 10.3275/7855. Epub 2011 Jul 7.

PMID:
21738005
47.

Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.

Gioiello A, Macchiarulo A, Carotti A, Filipponi P, Costantino G, Rizzo G, Adorini L, Pellicciari R.

Bioorg Med Chem. 2011 Apr 15;19(8):2650-8. doi: 10.1016/j.bmc.2011.03.004. Epub 2011 Mar 10.

PMID:
21459580
48.

Vitamin D endocrine system and the immune response in rheumatic diseases.

Cutolo M, Plebani M, Shoenfeld Y, Adorini L, Tincani A.

Vitam Horm. 2011;86:327-51. doi: 10.1016/B978-0-12-386960-9.00014-9. Review.

PMID:
21419278
49.

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW.

Gut. 2011 Apr;60(4):463-72. doi: 10.1136/gut.2010.212159. Epub 2011 Jan 17.

PMID:
21242261
50.

Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes.

Morelli A, Vignozzi L, Maggi M, Adorini L.

Biochim Biophys Acta. 2011 Aug;1812(8):859-66. doi: 10.1016/j.bbadis.2010.10.013. Epub 2010 Nov 5. Review.

Supplemental Content

Loading ...
Support Center